URGENT: This Altcoin Opportunity Won’t Wait – Act Now

Crypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happens like clockwork every 4 years, during the December to February window of a Bitcoin halving year. This is where fortunes are made – often LITERALLY overnight.

Richard Scheller Biography and Net Worth

Insider of BridgeBio Pharma

Richard H. Scheller, Ph.D. has served as a member of our Board of Directors since January 2018 and as our Chairman of Research & Development effective as of January 2019. Dr. Scheller served as the Chief Science Officer and Head of Therapeutics at 23andMe, a personal genetics company, from 2015 to April 2019. Previously, Dr. Scheller was the Executive Vice President of Research and Early Development and a member of the Executive Committee at Genentech, Inc., a biotechnology corporation, from February 2001 to December 2014. From January 2009 to December 2014, Dr. Scheller was also a member of the Enlarged Executive Committee at Hoffmann-La Roche Ltd, a pharmaceutical company. Dr. Scheller currently serves as a member of the board of directors ORIC Pharmaceuticals, Inc., a biopharmaceutical company, since February 2015, Alector, Inc., a biopharmaceutical company (Nasdaq: ALEC), since October 2018, DiCE Molecules, a biopharmaceutical company, and Maze Therapeutics, a biopharmaceutical company, since July 2019. Dr. Scheller holds a B.Sc. in Biochemistry from the University of Wisconsin-Madison and a Ph.D. in Chemistry from the California Institute of Technology. He completed his post-doctorate in Molecular Neurobiology at Columbia University and was also a post-doctorate fellow at California Institute of Technology. Dr. Scheller’s qualifications to serve on our Board of Directors include his scientific background and his senior management experience in the pharmaceutical industry.

What is Richard H. Scheller's net worth?: The estimated net worth of Richard H. Scheller is at least $223,231.23 as of May 5th, 2023. Dr. Scheller owns 8,427 shares of BridgeBio Pharma stock worth more than $223,231 as of December 21st. This net worth evaluation does not reflect any other assets that Dr. Scheller may own. Additionally, Dr. Scheller receives a salary of $509,620.00 as Insider at BridgeBio Pharma. Learn More about Richard H. Scheller's net worth.
How old is Richard H. Scheller?: Dr. Scheller is currently 71 years old. There are 7 older executives and no younger executives at BridgeBio Pharma. The oldest executive at BridgeBio Pharma is Dr. Charles J. Homcy M.D., Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director, who is 76 years old. Learn More on Richard H. Scheller's age.
What is Richard H. Scheller's salary?: As the Insider of BridgeBio Pharma, Inc., Dr. Scheller earns $509,620.00 per year. There are 5 executives that earn more than Dr. Scheller. The highest earning executive at BridgeBio Pharma is Dr. Neil Kumar Ph.D., Co-Founder, President, CEO & Director, who commands a salary of $1,530,000.00 per year. Learn More on Richard H. Scheller's salary.
How do I contact Richard H. Scheller?: The corporate mailing address for Dr. Scheller and other BridgeBio Pharma executives is 421 Kipling Street, Palo Alto CA, 94301. BridgeBio Pharma can also be reached via phone at (650) 391-9740. Learn More on Richard H. Scheller's contact information.
Has Richard H. Scheller been buying or selling shares of BridgeBio Pharma?: Richard H. Scheller has not been actively trading shares of BridgeBio Pharma over the course of the past ninety days. Most recently, Richard H. Scheller sold 13,777 shares of the business's stock in a transaction on Wednesday, August 4th. The shares were sold at an average price of $53.23, for a transaction totalling $733,349.71. Learn More on Richard H. Scheller's trading history.
Who are BridgeBio Pharma's active insiders?: BridgeBio Pharma's insider roster includes Douglas Dachille (Director), Ronald Daniels (Director), Neil Kumar (CEO), Frank McCormick (Director), Richard Scheller (Insider), Randal Scott (Director), Brian Stephenson (CFO), and Hannah Valantine (Director). Learn More on BridgeBio Pharma's active insiders.
Are insiders buying or selling shares of BridgeBio Pharma?: In the last year, insiders at the sold shares 9 times. They sold a total of 5,969,504 shares worth more than $155,266,267.36. The most recent insider tranaction occured on November, 19th when CEO Neil Kumar sold 27,389 shares worth more than $613,787.49. Insiders at BridgeBio Pharma own 24.7% of the company. Learn More about insider trades at BridgeBio Pharma.
Information on this page was last updated on 11/19/2024.

Richard H. Scheller Insider Trading History at BridgeBio Pharma

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
8/4/2021	Sell	13,777	$53.23	$733,349.71
12/21/2020	Sell	60,401	$65.32	$3,945,393.32	91,333

Richard H. Scheller Buying and Selling Activity at BridgeBio Pharma

BridgeBio Pharma Company Overview

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Today's Range

Now: $26.49

$26.02

$26.90

50 Day Range

MA: $25.79

$22.35

$29.50

2 Week Range

Now: $26.49

$21.62

$44.32

Volume

4,196,339 shs

Average Volume

1,922,665 shs

Market Capitalization

$5.01 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.08

URGENT: This Altcoin Opportunity Won’t Wait – Act Now

From Crypto Swap Profits | Ad

>> Register for the Workshop Now

Richard Scheller Biography and Net Worth

What is Richard H. Scheller's net worth?

How old is Richard H. Scheller?

What is Richard H. Scheller's salary?

How do I contact Richard H. Scheller?

Has Richard H. Scheller been buying or selling shares of BridgeBio Pharma?

Who are BridgeBio Pharma's active insiders?

Are insiders buying or selling shares of BridgeBio Pharma?